Transmedics Group, Inc. · NASDAQ:TMDX
Transmedics — Investor Presentation (January 2020)
24 slides from Transmedics's investor presentation, Jan 13, 2020
Slide 1: Redefining What's Possible in Organ Transplantation
Exhibit 99.1 Organ Care System (OCS’) Gi TransMedics. Redefining What's Possible — in Organ Transplantation Paradigm shifting technology that is transforming organ transplantation to a more dynamic environment 6a & The OCS is the only technology platform q ¥ \ addressing lung, heart and liver transp
Slide 2: Cautionary Note Regarding Forward-Looking Statements
DBD Donors Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our results of operations, commercial opportunity and the rate of
Slide 3: Organ Transplant Therapy Benefits and Challenges
Organ Transplant Therapy Benefits and Challenges PATIENTS: Longer life expectancy Better quality of life PROVIDERS: Treatment of choice for end-stage organ failure Revenue growth PAYORS: Cost-effective treatment for end-stage organ failure Benefits of Transplantation Current Market Challenges LOW UT
Slide 4: Organ Preservation Lacked Innovation for 4 Decades
Pre-Transplant Innovations Medical Management Mechanical Circulatory Support Devices Cardiac Synchronization Devices Renal Dialysis Organ Preservation Lacked Innovation for 4 Decades – Critical Missing Link Post-Transplant Innovations Surgical Techniques Anesthesia & Critical Care Post-Operative Car
Slide 5: Cold Storage Limits Utilization of Donor Organs and Impacts Outcomes
Cold Storage Limits Utilization of Donor Organs and Has Been Shown to Negatively Impact Post-Transplant Outcomes Significant Under Utilization Only 2-3 out of 10 thoracic organs are used Cold Storage Challenging Post- Transplant Clinical Outcomes Severe Time-Dependent Injury (Ischemia) No Organ Opti
Slide 6: Transplantation is a Supply Constrained Market
DBD Donors: 23% Lungs – 32% Heart Utilization DCD Donors: <5% Lung Utilization 0% Heart Utilization Transplantation is a Supply Constrained Market Due To Limitations of Cold Storage Preservation Method LUNG FAILURE HEART FAILURE LIVER FAILURE KIDNEY FAILURE DEMAND DBD Donors ~19,000 Annually DCD Don
Slide 7: Organ Preservation is a Critical Weak Link
Organ Preservation is a Critical Weak Link Between Pre- and Post-Transplant State for Transplant Recipients
Slide 8: Significant Market Opportunity for Currently Unutilized Organs
DCD Donors DBD Donors 67,000 Total Donors Significant Market Opportunity for Currently Unutilized Organs Estimated Annual Donor Pools: U.S., Canada, E.U. and Australia Source: OPTN; Global Observatory on Donation and Transplantation; Institute of Medicine of the National Academy of Science (2006) Si
Slide 9: TransMedics Organ Care System (OCS) – Transforming Organ Transplantation
TransMedics Organ Care System (OCS™) – Transforming Organ Transplantation OCS Significant Reduction in Ischemia Enable Organ Optimization Outside of the Human Body Allow for Organ Viability Assessment 81-87% Utilization of Donor Lungs & Hearts 10-14% Post-transplant Complications Significant Improve
Slide 10: GW TransMedics.
GW TransMedics. Trane aan:
Slide 11: The OCS Impact on Donor Organ Utilization
The OCS™ Impact on Donor Organ Utilization OCS Lungs Utilized for Transplants OCS Hearts Utilized for Transplants OCS DCD Hearts Utilized for Transplants OCS Lung EXPAND Trial Results OCS Heart EXPAND Trial Results OCS Heart OUS Commercial Use 0%
Slide 12: Pushing Historical Boundaries of Cold Storage
Pushing Historical Boundaries of Cold Storage 20+ Hours Time from Donor to Recipient Raleigh, NC Hawaii 4,700 Miles
Slide 13: OCS Enables an $8.0 Billion Potential Annual Opportunity
$Million OCS™ Enables an $8.0 Billion Potential Annual Opportunity Total OCS Annual Opportunity OCS Enabled DBD Transplants Current Transplants OCS Enabled DCD Transplants
Slide 14: Significant Multi-Organ Opportunity with Proven Evidence
Significant Multi-Organ Opportunity with Proven Evidence * Nicoara A., et al. Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors; Am J Transplant. 2018;18:1461–1470. Hospital Profit Margin and Hospital Top-Line Transplant Revenue 50% Reduction of se
Slide 15: OCS Product Offering – Disposable-Driven Business
OCS™ Product Offering – Disposable-Driven Business OCS Perfusion Set OCS Solutions OCS Console Hardware Single-Use Disposables
Slide 16: Key Market Drivers
Increase transplant volume Achieve better clinical outcomes Drive revenue and margin Achieve center of excellence status with payors Meet CMS performance metrics for outcomes Clinical Users Transplant Centers Key Market Drivers Utilize and allocate more donor organs for transplantation Meet their pe
Slide 17: Ultraconcentrated Industry With Significant Overlap Between Organs
Liver Heart Lung Sources: OPTN Annual Report 2016, Global Observatory on Donation & Transplantation 2017 Newsletter Ultraconcentrated Industry With Significant Overlap Between Organs ~50-55 Transplant Centers Drive 70% of Lung, Heart and Liver Transplants in the U.S.
Slide 18: OCS Centers in the U.S. – Lung, Heart & Liver Centers
OCS Centers in the U.S. – Lung, Heart & Liver Centers
Slide 19: TransMedics Strategy
Leverage the existing clinical knowledge base already in place to drive deeper utilization before expanding into new centers Use post-market registries to drive deeper adoption & expand clinical indications Minimize logistical barriers to broader adoption Deeper Clinical Adoption/Utilization TransMe
Slide 20: National Medicare Coverage for OCS Already Achieved
National Medicare Coverage for OCS™ Lung, Heart and Liver Transplants Already Achieved During U.S. Pivotal Trials & Lung Commercialization Potential Economic Benefits Further Support Market Adoption Positive System-Wide Impact for Multiple Stakeholders Improved access to cost effective organ transpl
Slide 21: Potential Growth Catalysts anticipated for 2020 & Beyond
Potential Growth Catalysts anticipated for 2020 & Beyond Continue to Drive Deeper Adoption and Utilization of OCS Lung FDA Panel in Q1 FDA PMA Approval Q2 U.S. Launch DBD Indication Q3 OCS Heart DCD Trial – Actively Enrolling (10/55 patients transplanted to date) File PMA to FDA Q2 PROTECT Trial Rea
Slide 22: TransMedics – Distancing from the Competition
GLOBAL PRESENCE Established Presence at Leading Global Academic Transplant Centers TECHNOLOGY Technology Customized to Fit in Current Work Flow VERSATILE The Only Multi-Organ Platform INDICATIONS Multiple Possible FDA PMAs for New Indications EVIDENCE Established Body of Global Clinical Evidence IP
Slide 23: TransMedics: Significant Growth Opportunity
TransMedics: Significant Growth Opportunity $8 Billion Greenfield Opportunity Paradigm Shifting Platform Technology Large Body of Clinical Evidence 2 FDA PMAs Approved 1 PMA Under Review & 1 Planned for 2020 Disposable-Driven Business Model Established U.S. Reimbursement 1,500+ Patients Have Receive
Slide 24: Organ Care System (OCS) Redefining What's Possible in Organ Transplantation
Organ Care System (OCS™) Redefining What’s Possible in Organ Transplantation
TransMedics Group — Investor Presentation (January 2020) on 6ix